ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2018, Vol. 27 ›› Issue (1): 84-88.DOI: 10.3969/j.issn.1006-298X.2018.01.019

• 论文 • 上一篇    下一篇

肾移植术后IgA肾病复发

  

  • 出版日期:2018-02-28 发布日期:2018-03-01

Management of recurrent IgA nephropathy following kidney transplantation

  • Online:2018-02-28 Published:2018-03-01

摘要:

IgA肾病(IgAN)是最常见的原发性肾小球疾病。肾移植术后IgAN复发率从45%~705%不等,其复发的危险因素包括供肾IgA沉积、亲属供者、受者年龄较小、原发病病程短、蛋白尿多、具有IgAN代表性的发病基因、术后过早停用激素、与供者HLA错配位点多等。随着近年来研究深入,人们认识到IgAN复发是影响移植肾长期存活的重要因素,新月体形成、肾小球硬化、间质纤维化、肾小球系膜区弥漫增生伴节段硬化或新月体形成等病理改变都是影响其预后的重要因素。复发性IgAN的治疗仍采用原发性IgAN的治疗方案,效果不佳者可给予大剂量激素和环磷酰胺治疗,但目前仍然需要研究新的治疗方法来进一步提高其移植肾的存活率。

关键词: 肾移植, IgA肾病, 复发

Abstract:

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in both the native kidney and renal allografts. The reported incidence of IgAN recurrence after renal transplantation varies from 45% to 705%. Main risk factors for IgAN recurrence include IgA deposition in the donor kidney, livingrelated donor, younger recipients, rapid progress in the native kidney, massive urinary protein excretion, the representative pathogenic genes of IgA nephropathy, early steroid withdrawal after kidney transplantation and high HLA mismatch. With further studies, it was found that the recurrence of IgAN could influence allograft longterm survival. Histopathological changes influencing allograft prognosis include crescent formation, glomerulosclerosis, interstital fibrosis, diffuse mesangial proliferation with segmental glomerulosclerosis or formation of crescents. Currently, treatment protocols for recurrent allograft IgAN are similar with those used for IgAN of the native kidneys. Highdose steroids or cyclophosphamide also can be administered for selected patients who respond poorly to conventional therapies. Nevertheless, new therapeutic regimens are still needed to improve allograft survival.

Key words: renal transplantation, IgA nephropathy, recurrence